ubmslateNT-logo-ubm

NT Mobile Menu

Search form

Topics:

All Content

Approved for patients with relapsing forms of MS, the drug generally should be reserved for those who have had an inadequate response to 2 or more drugs indicated for MS treatment.

Up until now, these treatments have not produced promising efficacy results in clinical trials. MRI could show the way.

As more treatments become available, patients will have more preferences and will play a more prominent role in directing choices.

Some very recent research findings have added to the literature on the associations between migraine and depression, anxiety, and other disorders. Highlights here.

Determining who is at risk for MS remains difficult, and symptoms may take time to develop even in patients who already have some destroyed myelin. MRI may help.

The emergence of Ioflupane I 123 Injection (DaTSCAN) provides clinicians with helpful information to differentiate idiopathic Parkinson disease from other diseases.

Could the common herpes simplex virus be associated with Alzheimer disease? These researchers think it is possible.

Patients with juvenile myoclonic epilepsy appear to have modest cognitive defects and imaging abnormalities early on that are unlikely to be associated with anti-epileptic therapy. This is a clear departure from traditional teaching.

A new study provides hope for MS treatment with IGF-1, which could ultimately halt the attack of T effector cells on myelin, thereby stopping disease progression.

Here: 5 new things to know about stroke -- its link with perioperative A-fib; the danger of cocaine; rehab possibilities with an Alzheimer drug; reducing stroke risk with potassium; and a potential screen for occult A-fib after cryptogenic stroke.

Pages

By clicking Accept, you agree to become a member of the UBM Medica Community.